Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
AssigneeShionogi & Co., Ltd.
InventorMakoto Kawai
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.
Claims57
A method for treating a disease caused by a virus having cap-dependent endonuclease comprising administering to a patient in need thereof a crystal of the compound of the following formula:
- wherein the crystal is selected from the group consisting of:
- (i) crystal Form I having two or more peaks in diffraction angles (2θ) selected from 8.6±0.2°, 14.1±0.2°, 17.4±0.2°, 20.0±0.2°, 24.0±0.2°, 26.3±0.2°, 29.6±0.2° and 35.4±0.2° in an X-ray powder diffraction spectrum,
- (ii) crystal Form II having two or more peaks in diffraction angles (2θ) selected from 4.4±0.2°, 8.9±0.2°, 11.7±0.2°, 14.9±0.2°, 22.3±0.2°, 24.4±0.2°, 28.0±0.2° and 31.5±0.2° in an X-ray powder diffraction spectrum, and
- (iii) crystal Form III having two or more peaks in diffraction angles (2θ) selected from 4.4±0.2°, 8.7±0.2°, 10.6±0.2°, 17.3±0.2°, 17.5±0.2°, 22.0±0.2°, 24.0±0.2°, 24.1±0.2° and 31.0±0.2° in an X-ray powder diffraction spectrum.
A method for treating influenza comprising administering to a patient in need thereof a crystal of the compound of the following formula:
- wherein the crystal is selected from the group consisting of:
- (i) crystal Form I having two or more peaks in diffraction angles (2θ) selected from 8.6±0.2°, 14.1±0.2°, 17.4±0.2°, 20.0±0.2°, 24.0±0.2°, 26.3±0.2°, 29.6±0.2° and 35.4±0.2° in an X-ray powder diffraction spectrum,
- (ii) crystal Form II having two or more peaks in diffraction angles (2θ) selected from 4.4±0.2°, 8.9±0.2°, 11.7±0.2°, 14.9±0.2°, 22.3±0.2°, 24.4±0.2°, 28.0±0.2° and 31.5±0.2° in an X-ray powder diffraction spectrum, and
- (iii) crystal Form III having two or more peaks in diffraction angles (2θ) selected from 4.4±0.2°, 8.7±0.2°, 10.6±0.2°, 17.3±0.2°, 17.5±0.2°, 22.0±0.2°, 24.0±0.2°, 24.1±0.2° and 31.0±0.2° in an X-ray powder diffraction spectrum.
A method for preventing influenza comprising administering to a patient in need thereof a crystal of the compound of the following formula:
- wherein the crystal is selected from the group consisting of:
- (i) crystal Form I having two or more peaks in diffraction angles (2θ) selected from 8.6±0.2°, 14.1±0.2°, 17.4±0.2°, 20.0±0.2°, 24.0±0.2°, 26.3±0.2°, 29.6±0.2° and 35.4±0.2° in an X-ray powder diffraction spectrum,
- (ii) crystal Form II having two or more peaks in diffraction angles (2θ) selected from 4.4±0.2°, 8.9±0.2°, 11.7±0.2°, 14.9±0.2°, 22.3±0.2°, 24.4±0.2°, 28.0±0.2° and 31.5±0.2° in an X-ray powder diffraction spectrum, and
- (iii) crystal Form III having two or more peaks in diffraction angles (2θ) selected from 4.4±0.2°, 8.7±0.2°, 10.6±0.2°, 17.3±0.2°, 17.5±0.2°, 22.0±0.2°, 24.0±0.2°, 24.1±0.2° and 31.0±0.2° in an X-ray powder diffraction spectrum.
Dependencies are inferred from the claim text.